Conclusion. The rates of mortality attributable to RA have declined globally. However, we observed substantial between-country disparities in RA mortality, although these disparities decreased over time. Population aging combined with a decline in RA mortality may lead to an increase in the economic burden of disease that should be taken into consideration in policy-making.
Rheumatoid arthritis (RA) affects ;0.5-1.0% of the adult population in most developed countries (1) . The global prevalence of RA is reported to be somewhat lower (;0.24%), with a 3 times higher prevalence in women compared with men (2) . RA is associated with reduced mobility, disability, poor quality of life, and death. Globally, RA accounted for 0.49% of years lived with disability and 0.19% of disability-adjusted life-years in 2010 (2) . Approximately one-fourth of RA patients are reported to have work disability within 3 years of diagnosis, and ;35% of patients are reported to have work disability within 10 years (3).
It is well recognized that the risk of death is higher in patients with RA compared with that in the general population, with the lifespan of RA patients being shortened by 4-10 years (4) . A recent meta-analysis showed that the standardized mortality ratio was 1.5 in patients with RA, and that this ratio remained stable over time (5) . Several studies have investigated RA as the underlying cause of death (UCD), and the observed proportion of RA deaths from all causes ranged from 0.03% in Sao Paolo, Brazil (6) to 0.17% in Sweden (7) .
Although previous studies demonstrated a stable or declining trend over time in RA mortality, these studies were conducted in a single state or a single country. One meta-analysis combined data from different single-era studies and suggested that the trend decreased (5). However, there has been no comprehensive assessment of mortality trends in RA over time, using repeated data from the same countries. The aim of the current study was to address the knowledge gap regarding potential crosscountry differences in RA mortality as the UCD and to Joinpoint regression analysis identifies points with a significant change in trend ("joinpoints") and determines linear trends between joinpoints (9). For each joinpoint, an annual percent change (APC) is estimated by fitting a regression line to the natural logarithm of the ASMRs, using calendar year as a predictor. The average APC as the weighted average of APCs was computed to provide a summary measure of the trend for the whole time period.
Analysis of between-country disparity. The absolute between-country disparity was measured using between-country variance, which is equal to the sum of the squared differences in each country ASMR from the pooled ASMR of all countries and weighted by each country's proportion of the total population of all countries (10) . The relative between-country disparity was measured by Gini coefficient based on use of the Lorenz curve to plot the cumulative share of population ranked by RA mortality rate, in increasing order, against the cumulative share of RA mortality (10) . The Gini coefficient is equal to twice the area between the Lorenz curve and the diagonal line. Its value ranges from 0 (perfect equality) to 1 (maximum possible inequality).
Decomposition analysis. The drivers of changes in the number of RA-associated deaths between 1987 and 2011 were decomposed into 3 components (population growth, population aging, and epidemiologic changes) (11) . The expected number of RA-associated deaths in 2011 was computed using 2 counterfactual scenarios: 1) population growth scenario, in which the size of the population in 2011 was considered to have the same age and sex structure and RA death rates as in 1987, and 2) population growth and aging scenario, in which the size of the population in 2011 had the actual age-sex structure of 2011, but RA death rates were the same as those in 1987. The difference between the actual number of deaths in 1987 and the expected number in scenario 1 is change due to population growth. The difference between the expected number of deaths in scenarios 1 and 2 is change due to population aging. The difference between the actual number of deaths in 2011 and the expected number in scenario 2 is change due to epidemiologic changes. The epidemiologic changes are changes in the age-, sex-, and cause-specific rates of death and include all changes in mortality that cannot be explained by population growth and aging (11) . The actual change in the number of deaths is equal to the net change in these components.
RESULTS
Number of deaths. During 1987-2011, a total of 219,189 patients in 31 countries died, in whom RA was registered as the UCD. These deaths represent 22.2% of total deaths attributed to musculoskeletal disorder deaths and 0.1% of all-cause deaths (see Supplementary Figure 1 Age-standardized mortality rate. The mean ASMR, on average for all countries over the entire time period, was 5.2 per million person-years (3.0 per million person-years in men and 6.7 per million person-years in women, corresponding to a female/male rate ratio of 2.25 [95% confidence interval 2.23-2.26]). Singapore and Finland had the lowest and the highest mean ASMRs, respectively (Figure 2 ). Female/male rate ratios were .1 in all countries, ranging from 1.79 in Belgium to 3.38 in the Czech Republic (see Supplementary Table 3 , available on the Arthritis & Rheumatology web site at http:// onlinelibrary.wiley.com/doi/10.1002/art.40091/abstract).
The mean age-standardized RA mortality rate declined Table 1) . Reductions of $25% were observed in 21 countries, while corresponding increases were seen only in Croatia, Israel, and Slovenia. In absolute terms, the greatest reduction in the ASMR in patients with RA was observed in Finland (20.6 fewer deaths per million person-years), and the greatest increase was seen in Croatia (3.7 more deaths per million person-years). Although the age-standardized female/male RA mortality rate ratio slightly declined from 2.28 in 1987-1989 to 2.19 in 2009-2011, the absolute difference decreased from 5.1 deaths per million person-years to 2.6 deaths per million person-years.
Age-specific RA mortality rates declined in all age groups, with the greatest reduction observed in the youngest age group and the smallest reduction observed in the 2 oldest age groups (see Supplementary Figure 2 , available on the Arthritis & Rheumatology web site at http://onlinelibrary. wiley.com/doi/10.1002/art.40091/abstract). However, there were between-country variations in age-specific RA mortality rates, particularly in older age groups (e.g., age-specific RA mortality rates in the 2 oldest age groups increased in 10 countries).
Joinpoint regression analysis. The Joinpoint regression analyses (see Supplementary Figure 3 and Supplementary (Supplementary Figure 4) , both reflecting declined between-country disparity over time.
Drivers of changes in the number of RA deaths. Despite population growth and population aging, the number of RA deaths declined from 1987 to 2001 because of a large reduction due to epidemiologic changes (see Supplementary Table 5 , available on the Arthritis & Rheumatology web site at http://onlinelibrary.wiley.com/doi/10.1002/art. 40091/abstract). In 23 countries, the number of RA deaths increased due to population growth and population aging and decreased due to epidemiologic changes. In 15 of these countries, this combination led to a decline in the number of RA deaths. In 5 countries, the number of deaths due to all 3 components increased. In Bulgaria, Hungary, and Croatia, the number of deaths due to population growth decreased. However, in Hungary and Croatia only, this reduction was accompanied by declines due to epidemiologic changes, which led to actual decreases in the number of RA deaths.
DISCUSSION
In the current study, the first cross-country analysis of mortality with RA as the UCD was conducted. On average, the number of RA deaths, the proportion of these deaths relative to musculoskeletal-and all-cause deaths, and RA ASMRs declined over the study period. However, there were substantial between-country disparities in the magnitude and temporal trend of RA deaths, although the disparities decreased over time.
It has been suggested that changes in the management of RA toward early and aggressive treatment with disease-modifying antirheumatic drugs (DMARDs) and subsequent biologic therapies has led to better health status and lower mortality over time for most patients with RA (4, 5) . In addition, it has been suggested that RA may be becoming a milder disease in general (12) . Furthermore, large reductions in the prevalence of smoking in patients with RA over recent decades, improvements in diagnosis, increased public awareness of RA, and general improvements in cardiovascular mortality might also partially explain the observed declining trend in our study. Comparing RA mortality with all-cause mortality in 29 countries for which our study had complete data (excluding Italy and Poland) suggested that the RA mortality rate declined at a higher pace compared with all-cause mortality over the study period (3.1% versus 1.7% annual reduction). A recent study using data from the UK indicated a greater degree of improvement in RA mortality rates compared with that in the general UK population between 1999 and 2014 (13) . The findings from the Global Burden of Disease Study (http://vizhub.healthdata.org/epi/) suggest that in highincome countries, the prevalence and incidence of RA increased in both sexes during 1990-2011. These findings, in addition to aging of the population and a decline in mortality, may lead to an increase in the number of patients with RA. Given that it appears that patients with RA are now living longer, an increase in the burden of RA on healthcare systems is expected, and policy makers should be aware of this to appropriately plan for this anticipated increase.
The magnitude and temporal trend of RA mortality varied across countries. We observed that countries in northern Europe, on average, had a higher mortality rate compared with the rate in other regions. Higher incidence and prevalence rates of RA in northern European and North American countries compared with that in southern European and developing countries have been previously reported (14) and might partially explain our finding. Moreover, differences in the genetic, epidemiologic, and clinical profile of RA, distribution of RA risk factors including environmental exposures, and socioeconomic status might also partially explain our findings (14) . Betweencountry disparities in the validity and use of the RA diagnosis and access to treatments including DMARDs might be other potential reasons for the observed disparity in RA mortality. Moreover, the impact of differences in cause-ofdeath coding practices, including time of the introduction of ICD-10, cannot be ruled out, although this cannot explain the observed disparities in the most recent decade, because most countries were applying ICD-10 during this time period. Furthermore, although most countries included in our study have a vital statistics registration with satisfactory quality (15) , differences in quality of cause-ofdeath registration might still be another potential reason for the observed disparities in RA mortality.
Several limitations of this study should be considered when interpreting the findings. It is known that RA is underreported as the UCD on death certificates (4). The registration, reporting, and analysis of contributory causes of death would have alleviated this problem, but such data are, unfortunately, not available at present. In addition, cause-of-death registrations are subject to errors and incompleteness. Variations in attribution of causes of death, underreporting, and inaccuracy across countries and over time are of concern. Change in ICD revisions might produce discontinuities in mortality data and can bias mortality trends. However, in many countries RA mortality rates started to decline prior to the introduction of ICD-10, implying that the observed decreasing trend is not artificial. Most of the countries included in this study are highincome countries, implying that generalizability of the results to low-and middle-income countries is limited. The small number of RA deaths might limit the power of joinpoint modeling to detect significant joinpoints. In addition, the wide confidence intervals for the average APC in some countries and also the sensitivity of our betweencountry disparity measures to outliers call for caution when interpreting the results. This is a descriptive aggregate-level analysis, and all given explanations for mortality trends are speculative, and no causal inference can be made.
Herein, we report the first cross-country analysis of mortality with RA as the UCD, strongly suggesting that RA mortality decreased in many countries over a 25-year period. There were substantial but declining between-country disparities in RA mortality, with countries in northern Europe having the highest RA mortality rates. An increase in the number of patients with RA due to population aging combined with a reduction in RA-associated mortality imply that the burden of disease will increase in coming decades, and this should be taken into consideration in policy-making by international and national health authorities.
